Paul Matias

Analyst

Stifel

Equibles does not estimate personal net worth.

About Paul Matias

Paul Matias is recorded as Analyst at Stifel. Paul Matias has spoken on 3 earnings calls and 2 other investor events across 3 companies, most recently for Sionna Therapeutics, Inc. on September 14, 2026. Those appearances were for Sionna Therapeutics, Inc. (SION), Biogen Inc. (BIIB) and Alkermes plc. (ALKS). The companies whose calls Paul Matias spoke on are classified in the Healthcare sector.

Paul Matias on recent calls

“Can you maybe quantify a little bit more the changes in Trikafta that you saw? Like, is that – were those down – are these decreases in choice hats big enough to explain what happened here?”

Analyst — Stifel, Sionna Therapeutics, Inc. Q2 FY2026 Earnings Call · September 14, 2026

“Can you maybe quantify a little bit more the changes in Trikafta that you saw? Like, is that, were those down, I guess, decreases in TROCAPs are big enough to explain what happened here?”

Analyst — Stifel, Sionna's Topline Data Presentation for SION-719 Phase 2a and SION-451 Dual Combination Phase 1 · August 10, 2026

“How are you guys thinking about the brain shuttle space right now? And as you think about yourselves investing so much in building this Alzheimer's market, do you feel like Biogen needs to have a brain shuttle to capture what the peak of sales potential of A-Beta is going to look like?”

Analyst — Stifel, Biogen Inc. Q2 FY2026 Earnings Call · July 29, 2026

“Hey, thanks for taking my questions, and Richard, congrats on the transition, and Blair, congrats to you as well. Another one on ADHD, can you maybe just talk a little bit about how you selected the doses for this study?”

Analyst — Stifel, Q2 2026 Alkermes plc Earnings Conference Call · July 28, 2026